Rep. Lisa C. McClain Buys Novartis AG (NYSE:NVS) Shares

Representative Lisa C. McClain (R-Michigan) recently bought shares of Novartis AG (NYSE:NVS). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in Novartis stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Novartis Stock Performance

Shares of NVS opened at $130.23 on Friday. The company has a market cap of $275.09 billion, a PE ratio of 17.79, a price-to-earnings-growth ratio of 1.93 and a beta of 0.60. The firm has a 50-day moving average of $128.31 and a 200-day moving average of $122.51. Novartis AG has a one year low of $96.06 and a one year high of $134.00. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.88 and a quick ratio of 0.62.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.26 by ($0.01). Novartis had a net margin of 26.49% and a return on equity of 41.21%. The firm had revenue of $14.36 billion during the quarter, compared to the consensus estimate of $13.70 billion. During the same period in the previous year, the company posted $2.06 earnings per share. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. As a group, equities analysts forecast that Novartis AG will post 8.45 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on NVS shares. Wall Street Zen upgraded Novartis from a “hold” rating to a “buy” rating in a research note on Friday. The Goldman Sachs Group restated a “sell” rating and issued a $118.00 price target (down previously from $119.00) on shares of Novartis in a research note on Friday, September 12th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research report on Wednesday. Bank of America raised shares of Novartis from a “neutral” rating to a “buy” rating in a research report on Tuesday. Finally, Jefferies Financial Group restated a “hold” rating on shares of Novartis in a research note on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $122.33.

Institutional Investors Weigh In On Novartis

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GFG Capital LLC acquired a new position in shares of Novartis in the second quarter valued at about $26,000. WPG Advisers LLC bought a new stake in Novartis in the 1st quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Novartis during the 2nd quarter worth approximately $30,000. Valley Wealth Managers Inc. acquired a new position in shares of Novartis during the 3rd quarter worth approximately $31,000. Finally, Measured Wealth Private Client Group LLC bought a new position in shares of Novartis during the third quarter worth approximately $33,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.